Divi's Laboratories Ltd. Share Price

Overview

Divi's Laboratories Ltd. share price is currently ₹11,023.65, up by ₹30.10 (0.27%) from its previous closing price of ₹10,993.55. The share price has gained 21.54% over the past month and gained 71.94% over the past year. The stock's 52-week low and high are ₹5,528.30 and ₹11,662.05, respectively. Divi's Laboratories Ltd. has a market capitalisation of ₹ 2,97,324.80 Cr. The share price was last updated on 20 Nov 2026, 03:53 PM IST.

Divi's Laboratories Ltd.
Divi's Laboratories Ltd.
DIVISLAB
 ₹0.00
 ₹30.10
0.27%
Healthcare
 ₹0.00(%)1D

Updated: 20 Nov 2026, 03:53:35 pm IST

Market Data

Open Price

 ₹11,021.04

Prev. Close

 ₹10,993.55
 ₹10,865.40

Day Low

 ₹11,041.40

Day High

 ₹5,528.30

52 Week Low

 ₹11,662.05

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

86.86

Sector PE

46.21

PB Ratio

17.43

Sector PB

6.06

EPS

126.91

Dividend Yield

0.50

Today's Volume

422.432 K

5 Day Avg. Volume

642.970 K

PEG Ratio

5.05

Market Cap.

₹ 2,97,324.80 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 1500% at ₹30/Share
24-Jul-202624-Jul-2026
DividendsFinal Dividend of 1500% at ₹30/Share
25-Jul-202525-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
SBI Large Cap Fund - Regular Plan - Growth20.32 Lac
20.32 Lac
no change
SBI Aggressive Hybrid Fund - Regular Plan - IDCW17.00 Lac
17.00 Lac
no change
HDFC Flexi Cap Fund - Growth18.94 Lac
16.30 Lac
(13.94%)
SBI Focused Fund - Regular Plan - Growth13.00 Lac
13.00 Lac
no change
Axis Large Cap Fund - Regular Plan - Growth8.56 Lac
9.15 Lac
(6.89%)

About Divi's Laboratories Ltd. 👋

Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Quetiapine Fumarate, Naproxen Sodium, Olmesartan, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, and others. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies. It is engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company's subsidiaries include Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Pradeep Carpenter

Pradeep Carpenter

18 Nov • 2:32 PM · SEBI-Registered Analyst

Pharma Stocks Are Heating Up! Is Glenmark Next to Break Out?

Company Overview Glenmark Pharmaceuticals is a research-driven pharmaceutical company with operations across India, the US, Europe and emerging markets. Its portfolio includes branded formulations, generics, respiratory medicines and oncology products. Pharma Sector: The Bigger Picture The pharma sector is witnessing renewed buying interest, with stocks like Glenmark, Laurus Labs, Divi's Laboratories and other pharma companies attracting investor attention. Improving business growth, export opportunities and demand for specialty medicines are supporting sector sentiment. Why Glenmark Is in Focus Glenmark's Q2 FY27 performance highlighted strong business momentum, with approximately 20% like-for-like revenue growth. Emerging Markets revenue grew 33.2% YoY, while North America's core business grew around 31%. Its expanding oncology portfolio and international business provide additional growth opportunities. Technical View Glenmark is showing a strong bullish structure on the daily chart. The stock has rallied sharply from recent swing lows and is trading above its key moving averages. MACD remains positive, while RSI is around the bullish zone, indicating strong momentum. Key Levels: Immediate resistance: ₹2,690–2,715 Breakout confirmation: Above ₹2,715 Immediate support: ₹2,625–2,640 A sustained breakout above ₹2,715 with strong volumes could trigger another upward move. My View The bigger story is the improving momentum across the pharma sector. Glenmark is emerging as an interesting stock to watch, backed by business growth and a strong technical setup. A decisive breakout could bring fresh buying interest. Disclaimer: For educational purposes only. Not investment advice. Disclosure: The analyst or his family does not have any position in GLENMARK. GLENMARK

See More
Arthavrksh

Arthavrksh

10 Nov • 6:41 PM · SEBI-Registered Analyst

Nifty Pharma at Triangle Reference; RSI Caution

Nifty Pharma has broken out of its long triangle consolidation on the weekly chart and extended the rally. The index is now near 28,900, with a weekly high around 29,225. That is close to the measured-move reference of about 29,200 from the triangle breakout. RSI at about 73 shows strong momentum, but it is also forming a negative divergence, with price making higher highs while RSI makes lower highs. A similar setup was seen around September 2024, after which the index corrected. A negative divergence is only a caution and not a reversal signal by itself. A reversal candlestick near the top would add weight to the caution, and until then caution is the operative word. The 200-week SMA near 20,160 is far below, so the broader trend remains intact, but after a sharp advance, consolidation or profit booking would not be unusual. Heavyweights such as SUNPHARMA , Cipla, Dr. Reddy’s, Lupin and Divi’s Laboratories are worth tracking for how they behave from here. The weekly candle is still forming, so the closing structure matters. The weekly candle is still forming, so the closing structure matters. Negative RSI divergence at a pattern’s measured-move reference is a caution, not a sell signal; a reversal candlestick at the top gives it more weight. Disclaimer: This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

See More
Priyam Mehta

Priyam Mehta

9 Nov • 8:15 PM · SEBI-Registered Analyst

Net Profit Surges 64%, Revenue Jumps 35%

DIVISLAB **Divi's Laboratories: Net Profit Surges 64%, Revenue Jumps 35%** **DIVISLAB** Divi's Laboratories reported a strong Q2 FY27 performance, with consolidated net profit rising 63.6% year-on-year to ₹1,127 crore compared with ₹689 crore in Q2 FY26. **Why it matters:** Revenue from operations increased 35.4% to ₹3,676 crore, while EBITDA surged approximately 60.7% to ₹1,660 crore. EBITDA margin improved to 42.6% from 32.7% a year ago. The company's performance reflects strong business momentum and improved operating profitability. First-half consolidated net profit also increased to ₹2,029 crore from ₹1,234 crore. **My view:** Strong revenue growth, margin expansion and robust profitability highlight Divi's operational strength. However, sustaining these elevated margins and converting earnings into healthy cash flows will be important. **What to watch:** Custom synthesis growth, API demand, export business, capacity utilisation, EBITDA margins and operating cash flows. **Stance:** Divi's Laboratories continues to demonstrate strong earnings momentum. Investors should also evaluate valuations and sustainability of growth before making investment decisions. **Disclosure:** I am a SEBI Registered Research Analyst. This content is for educational and informational purposes only and is not investment advice or a recommendation to buy or sell any security. Investments in securities markets are subject to market risks.

See More
Kavan Patel

Kavan Patel

9 Nov • 3:19 PM · SEBI-Registered Analyst

Sensex, Bankex analysis for 9/11/2026 (MARKET ANALYSIS)

1. Sensex Analysis Current Level: 80,999 Trend & Bias: Bullish / Long-biased Key Support / Pivot Level: 79,000 Technical Outlook: Long Position Strategy: As long as Sensex trades and holds above 79,000, the bias remains positive. Traders holding long positions are advised to maintain them with 79,000 acting as a crucial structural support / stop-loss threshold. Short Position Strategy: A breakdown and sustained trade below 79,000 would invalidate the current bullish structure, signaling weakness and shifting momentum to the bears. Short positions should only be considered conditionally if this threshold is breached. 2. Bankex Analysis Current Level: 66,297 Trend & Bias: Bullish / Long-biased Key Support / Pivot Level: 64,600 Technical Outlook: Long Position Strategy: Bankex is currently positioned well above its critical support line. Maintaining levels above 64,600 favors holding existing long positions, as this acts as a major defense zone for buyers. Short Position Strategy: Caution is warranted if the index slips below 64,600. Short entries are strictly conditional upon a confirmed breakdown under this pivotal support zone. F&O top gainer was : DIVISLAB

See More
Manjushri Sharma

Manjushri Sharma

9 Nov • 3:02 PM · SEBI-Registered Analyst

Divi's Laboratories was trading at ₹11444 up approx 3.13%

DIVISLAB Divi's Laboratories was trading at ₹11444 up approximately 3.13% The market response reflects investor interest following the company's strong quarterly earnings. WHAT IS DRIVING THE PERFORMANCE? The company's growth reflects improved business performance across its pharmaceutical ingredients and related manufacturing operations. Divi's Laboratories is a major manufacturer of active pharmaceutical ingredients APIs intermediates and nutraceutical ingredients supplying customers in domestic and international markets. Strong revenue growth and higher profitability are important indicators that investors will continue to monitor. WHAT SHOULD INVESTORS WATCH NEXT? Market participants should track future revenue growth operating margins export demand manufacturing capacity utilisation and management commentary. While strong earnings can improve investor sentiment the sustainability of growth and the stock's valuation remain important considerations. INVESTOR WATCH Divi's Laboratories remains an important pharmaceutical stock to track. Investors should assess its technical structure trading volumes and broader pharmaceutical sector trends before making investment decisions.

See More
Saurab Jain

Saurab Jain

9 Nov • 12:36 PM · SEBI-Registered Analyst

Divi’s Labs hits record ₹11,824 on strong Q2 earnings

Divi’s Laboratories hit a record ₹11,824 on 9 November 2026 after Q2 results, with support seen near the ₹11,000 level. Divi’s Laboratories Limited [ DIVISLAB ] hit a fresh all-time high of ₹11,824 by 12:25 pm on 9 November 2026. The stock was up over 6% at the peak. The move follows Q2FY27 results. Revenue rose 35% year on year to ₹3,676 crore, led by Custom Synthesis, up 44% to ₹2,200 crore. EBITDA margin widened 989 basis points to 42.6%. Adjusted profit after tax grew 64% to ₹1,127 crore. Market capitalisation crossed ₹3 trillion for the first time. On the daily chart, the stock has broken out of a long range near ₹6,000 to ₹7,000 and has climbed in steps since. Volume on the latest bar is already near the higher readings of recent months. The trend is strongly bullish. At an all-time high, there is no overhead supply on the chart, so resistance is not defined. Support is at the ₹11,000 psychological level, just below the session low of ₹11,071. A daily close below ₹11,000 would weaken the setup. The stock is up 32% in 12 sessions, so a pause or profit booking would be normal. Watch whether it holds ₹11,000 and closes above ₹11,824 on strong volume. Stance: bullish while above ₹11,000. Disclosure I do not hold any position in this stock. This is not a recommendation to buy or sell. Investments in securities markets are subject to market risks. Read all related documents carefully before investing.

See More

News & Events

Frequently Asked Questions

What is the share price of Divi's Laboratories Ltd.?

What is the market cap of Divi's Laboratories Ltd.?

Should I buy Divi's Laboratories Ltd. stock now?

What is the 52 week high and low of Divi's Laboratories Ltd.?

Is the Divi's Laboratories Ltd. stock good to buy?

Is Divi's Laboratories Ltd. a good buy for the long term?

Is Divi's Laboratories Ltd. overvalued or undervalued?

What is the PE and PB ratio of Divi's Laboratories Ltd.?

Start Now